Last reviewed · How we verify
Compound Kushen Injection（CKI）
Compound Kushen Injection is a traditional Chinese medicine-derived herbal extract that exerts anti-tumor and immunomodulatory effects through multiple pathways including apoptosis induction and immune system activation.
Compound Kushen Injection is a traditional Chinese medicine-derived herbal extract that exerts anti-tumor and immunomodulatory effects through multiple pathways including apoptosis induction and immune system activation. Used for Adjunctive treatment in non-small cell lung cancer, Adjunctive treatment in gastric cancer, Adjunctive treatment in colorectal cancer.
At a glance
| Generic name | Compound Kushen Injection（CKI） |
|---|---|
| Also known as | Yanshu injection |
| Sponsor | Shanxi Zhendong Pharmacy Co., Ltd |
| Drug class | Herbal extract / Traditional Chinese medicine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
CKI is derived from Kushen (Sophora flavescens) and contains active alkaloid compounds that promote cancer cell apoptosis, inhibit tumor angiogenesis, and enhance immune function. The injection formulation is used primarily in combination with chemotherapy to improve treatment efficacy and reduce adverse effects in cancer patients.
Approved indications
- Adjunctive treatment in non-small cell lung cancer
- Adjunctive treatment in gastric cancer
- Adjunctive treatment in colorectal cancer
- Supportive care in cancer chemotherapy
Common side effects
- Injection site reactions
- Nausea
- Vomiting
- Allergic reactions
Key clinical trials
- Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer (PHASE4)
- Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma (PHASE2)
- Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer (PHASE4)
- Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
- The Randomized Controlled Clinical Trial of Kushen Injection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Compound Kushen Injection（CKI） CI brief — competitive landscape report
- Compound Kushen Injection（CKI） updates RSS · CI watch RSS
- Shanxi Zhendong Pharmacy Co., Ltd portfolio CI